Previous 10 | Next 10 |
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced it granted an exclusive option to Amasa Therapeutics, Inc. (Amasa), a privately-held biopharmaceut...
Lineage Cell Therapeutics (LCTX) announces that Kevin Cook will join as the Company’s Chief Financial Officer ((CFO)), effective June 21, 2021. Mr. Cook most recently served as Chief Operating Officer of a family office investment firm with an emphasis in the solar energy and infrastru...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Kevin Cook will join as the Company’s Chief Financial Officer, effective June 21, 2021. Mr...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at the Raymond James 2021 Human Heal...
Alzheimer’s disease (AD) is the most common cause of dementia, a progressively debilitating neurodegenerative disease that results in declining cognitive functions, inability to form new memories, behavioral disorders, and gradual loss of bodily functions. While older age does not cause...
I first covered Lineage last year when the stock was languishing under $1. Since that time, the company has steadily posted promising data for its potential dry AMD therapy, OpRegen. In this article, I take a look at that new data and provide updated thoughts on why I still like L...
Over the next two Fridays, The FTSE Russell will post updates to its equity index reconstitutions that were announced last Friday. These updates and adjustments to the original lists provided could occur for a number of reasons. The reactions to stock prices impacted could be strong as these a...
Lineage Cell Therapeutics (LCTX) is set to join the broad-market Russell 3000 Index as well as the Russell Microcap Index, effective after the U.S. market opens on June 28, 2021."We believe our inclusion in the Russell indexes will help broaden awareness of Lineage’s corporat...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that it is set to join the broad-market Russell 3000 ® Index as well as the Russell Microcap ...
In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...
News, Short Squeeze, Breakout and More Instantly...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000 ® Index, effective after...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tue...
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE America...